Leadership Preventive Medicine Residency, Department of Pediatrics, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire.
JAMA Pediatr. 2018 Apr 1;172(4):345-351. doi: 10.1001/jamapediatrics.2017.5195.
Rising incidence of neonatal abstinence syndrome (NAS) is straining perinatal care systems. Newborns with NAS traditionally receive care in neonatal intensive care units (NICUs), but rooming-in with mother and family has been proposed to reduce the use of pharmacotherapy, length of stay (LOS), and cost.
To systematically review and meta-analyze if rooming-in is associated with improved outcomes for newborns with NAS.
MEDLINE, CINAHL, The Cochrane Library, and clinicaltrials.gov were searched from inception through June 25, 2017.
This investigation included randomized clinical trials, cohort studies, quasi-experimental studies, and before-and-after quality improvement investigations comparing rooming-in vs standard NICU care for newborns with NAS.
Two independent investigators reviewed studies for inclusion. A random-effects model was used to pool dichotomous outcomes using risk ratio (RR) and 95% CI. The study evaluated continuous outcomes using weighted mean difference (WMD) and 95% CI.
The primary outcome was newborn treatment with pharmacotherapy. Secondary outcomes included LOS, inpatient cost, and harms from treatment, including in-hospital adverse events and readmission rates.
Of 413 publications, 6 studies (n = 549 [number of patients]) met inclusion criteria. In meta-analysis of 6 studies, there was consistent evidence that rooming-in is preferable to NICU care for reducing both the use of pharmacotherapy (RR, 0.37; 95% CI, 0.19-0.71; I2 = 85%) and LOS (WMD, -10.41 days; 95% CI, -16.84 to -3.98 days; I2 = 91%). Sensitivity analysis resolved the heterogeneity for the use of pharmacotherapy, significantly favoring rooming-in (RR, 0.32; 95% CI, 0.18-0.57; I2 = 13%). Three studies reported that inpatient costs were lower with rooming-in; however, significant heterogeneity precluded quantitative analysis. Qualitative analysis favored rooming-in over NICU care for increasing breastfeeding rates and discharge home in familial custody, but few studies reported on these outcomes. Rooming-in was not associated with higher rates of readmission or in-hospital adverse events.
Opioid-exposed newborns rooming-in with mother or other family members appear to be significantly less likely to be treated with pharmacotherapy and have substantial reductions in LOS compared with those cared for in NICUs. Rooming-in should be recommended as a preferred inpatient care model for NAS.
新生儿戒断综合征(NAS)的发病率不断上升,给围产期护理系统带来了压力。传统上,患有 NAS 的新生儿在新生儿重症监护病房(NICU)接受治疗,但有人提出母婴同室和家庭陪伴可以减少药物治疗的使用、住院时间(LOS)和成本。
系统回顾和荟萃分析母婴同室是否与改善患有 NAS 的新生儿的结局有关。
从开始到 2017 年 6 月 25 日,检索了 MEDLINE、CINAHL、The Cochrane Library 和 clinicaltrials.gov。
本研究纳入了比较母婴同室与 NAS 新生儿标准 NICU 护理的随机临床试验、队列研究、准实验研究和前后质量改进研究。
两名独立的研究者对纳入的研究进行了评估。使用风险比(RR)和 95%置信区间(CI)采用随机效应模型汇总二分类结局。使用加权均数差(WMD)和 95%CI 评估连续结局。
主要结局是新生儿接受药物治疗。次要结局包括 LOS、住院费用和治疗相关的危害,包括院内不良事件和再入院率。
在 413 篇论文中,有 6 项研究(n=549[患者数量])符合纳入标准。对 6 项研究的荟萃分析表明,母婴同室与 NICU 护理相比,可显著降低药物治疗的使用(RR,0.37;95%CI,0.19-0.71;I2=85%)和 LOS(WMD,-10.41 天;95%CI,-16.84 至-3.98 天;I2=91%)。敏感性分析解决了药物治疗使用的异质性问题,显著有利于母婴同室(RR,0.32;95%CI,0.18-0.57;I2=13%)。三项研究报告称,母婴同室的住院费用较低;然而,由于存在显著的异质性,因此无法进行定量分析。定性分析倾向于母婴同室而不是 NICU 护理,以增加母乳喂养率和在家庭监护下出院,但很少有研究报告这些结果。母婴同室与更高的再入院率或院内不良事件无关。
与在 NICU 中接受治疗的新生儿相比,与母亲或其他家庭成员母婴同室的阿片类药物暴露新生儿接受药物治疗的可能性明显降低,且 LOS 显著缩短。母婴同室应作为 NAS 的首选住院治疗模式。